For most people with relapsing-remitting multiple sclerosis (the most common form), flare-ups happen roughly once or twice a year without treatment. With modern disease-modifying therapies, that rate drops significantly, and some people go years between relapses. But flare frequency varies widely from person to person and changes over the course of the disease.
Average Flare Frequency
In the early years after diagnosis, untreated relapsing-remitting MS typically produces one to two relapses per year. Real-world data from UK MS clinics found an annualized relapse rate of about 0.08 among patients already receiving care, meaning that in a well-managed population, most people experience fewer than one relapse per year. That low number reflects the impact of disease-modifying therapies: in that same study, 36% of patients who did have a relapse were on treatment at the time, while the rest were not.
These are averages. Some people experience clusters of relapses in their first few years, then go quiet. Others have a steadier pattern. Your personal relapse rate depends on factors like how early you started treatment, which therapy you’re on, and individual disease biology that isn’t fully predictable.
How Treatment Changes the Pattern
Disease-modifying therapies are the single biggest factor in reducing flare frequency. Higher-efficacy medications can cut the relapse rate substantially. In one observational study published in Neurology, patients who switched to a high-efficacy therapy saw their relapse rate drop by roughly 0.44 relapses per year compared to their previous treatment. For someone who was flaring once or twice a year, that kind of reduction can mean going an entire year or longer without an episode.
Starting treatment early matters. The goal isn’t just to reduce the number of flares you experience but to prevent the cumulative nerve damage that each relapse can leave behind. People who begin therapy soon after diagnosis tend to have fewer relapses over the following decade compared to those who delay.
How Flares Change Over Time
MS flare patterns aren’t static. In the relapsing-remitting phase, relapses are driven by active inflammation in the brain and spinal cord. Over years or decades, some people transition to secondary progressive MS, where the nature of the disease shifts. Inflammation gradually decreases, and relapses become less frequent or stop altogether. But this isn’t necessarily good news: the disease instead causes a slow, steady worsening of function rather than the dramatic ups and downs of the earlier phase.
Not everyone transitions to secondary progressive MS. And for those who do, the timing varies widely, from a few years to several decades after diagnosis.
What Counts as a True Flare
Not every worsening of symptoms is a genuine relapse. Clinically, an episode qualifies as a relapse only when it meets three criteria: it happens at least 30 days after the last relapse, it lasts at least 24 hours, and it occurs without an infection or other explanation like a fever or urinary tract infection.
Most true relapses last from a few days to several weeks, and some stretch into months. They involve new neurological symptoms or a clear worsening of existing ones, things like new numbness, vision problems, difficulty walking, or unusual fatigue that goes beyond your baseline.
Pseudo-Relapses and Heat Sensitivity
Many people with MS experience temporary symptom flares that look and feel like relapses but aren’t caused by new inflammation. These pseudo-relapses are often triggered by heat. A rise in core body temperature as small as 0.25°F can produce symptoms because heat slows or blocks nerve signal transmission along nerves that are already damaged. Even warming just the skin, from direct sunshine or a hot room, can be enough.
Common triggers include hot weather, vigorous exercise, hot baths, and fevers from illness. The key difference is that pseudo-relapses resolve once your body cools down, usually within minutes to hours rather than days. They don’t represent new damage to the nervous system, but they can be alarming if you don’t recognize the pattern. Cooling strategies like cold vests, air conditioning, and avoiding midday heat can prevent most of these episodes.
Common Triggers for True Relapses
Infections are the most well-established trigger for genuine relapses. Upper respiratory infections, urinary tract infections, and other common illnesses can activate the immune system in ways that provoke new inflammatory attacks on nerve tissue. This is one reason neurologists emphasize staying current on vaccinations and treating infections promptly.
Stress is another significant factor. While the exact mechanism is complex, chronic or severe psychological stress is associated with increased relapse risk. The Consortium of Multiple Sclerosis Centers notes that stress is more likely to exacerbate MS symptoms and bring about a flare. Sleep deprivation, major life changes, and physical exhaustion can compound the effect. None of these triggers guarantee a relapse, but they shift the odds.
What Happens During a Flare
When a true relapse occurs, the first step is confirming that it’s not a pseudo-relapse driven by heat, infection, or stress. If symptoms are mild, your neurologist may recommend monitoring without intervention, since many relapses resolve on their own over weeks.
For more disruptive flares, the standard treatment is a short course of high-dose intravenous steroids, typically given over three to five days. Steroids don’t change the ultimate outcome of the relapse but can shorten its duration and speed recovery. For severe relapses that don’t respond to steroids, a procedure called plasmapheresis (which filters inflammatory proteins from the blood) is sometimes used.
Recovery from a relapse is unpredictable. Some people bounce back completely within a few weeks. Others recover most function but are left with residual symptoms. Over time, incomplete recovery from successive relapses is what drives long-term disability in MS, which is why reducing flare frequency through consistent treatment is so central to managing the disease.